Skip to search formSkip to main contentSkip to account menu

PCSK9 protein, human

Known as: proprotein convertase subtilisin kexin 9, human, Proprotein Convertase Subtilisin/Kexin Type 9, Neural Apoptosis Regulated Convertase 1 
Proprotein convertase subtilisin/kexin type 9 (692 aa, ~74 kDa) is encoded by the human PCSK9 gene. This protein is involved in the degradation of… 
National Institutes of Health

Related topics

Related topics

14 relations
Cell surfaceCholesterol HomeostasisEndopeptidasesEndoplasmic Reticulum

Broader (1)

Proprotein Convertase 9

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With…
Background: The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein… 
Review
2017
Review
2017
Epidemiology and management of hyperlipidemia.
Cardiovascular disease (CVD) is the leading cause of death among adults in the United States, and people with hyperlipidemia are… 
Highly Cited
2014
Highly Cited
2014
PCSK9 is a critical regulator of the innate immune response and septic shock outcome
Inhibition of PCSK9 function is associated with an increase in pathogen lipid clearance, a decrease in the innate immune… 
Review
2014
Review
2014
Resistance and intolerance to statins.
Highly Cited
2014
Highly Cited
2014
Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER…
Background— Evolocumab (AMG 145), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9… 
Highly Cited
2013
Highly Cited
2013
Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation*
Background: Secreted PCSK9 regulates LDL levels in plasma by mediating degradation of hepatic LDL receptors. Results: LDL binds… 
Highly Cited
2008
Highly Cited
2008
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density lipoprotein receptor (LDLR) protein levels and… 
Highly Cited
2007
Highly Cited
2007
Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis Published, JLR Papers in Press, April 20, 2007.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease that regulates low density lipoprotein receptor (LDLR… 
Highly Cited
2006
Highly Cited
2006
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.
Elevated levels of circulating low-density lipoprotein cholesterol (LDL-C) play a central role in the development of… 
Highly Cited
1987
Highly Cited
1987
Protein engineering of subtilisin BPN': enhanced stabilization through the introduction of two cysteines to form a disulfide bond.
Introduction of a disulfide bond by site-directed mutagenesis was found to enhance the stability of subtilisin BPN' (EC 3.4.21.14… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)